Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
José Ignacio
JI
Carrasco
Isabel
I
Izquierdo
Pilar
P
Medina
Miguel Ángel
MÁ
Arnau
Antonio
A
Salvador
Esther
E
Zorio
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000075224:Cardiac Conduction System Disease; D004562:Electrocardiography; D005260:Female; D005424:Flecainide / Q000627:therapeutic use*; D006579:Heterozygote; D006801:Humans; D007223:Infant; D008133:Long QT Syndrome / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation / Q000502:physiology; D062554:NAV1.5 Voltage-Gated Sodium Channel / Q000235:genetics*
D000889:Anti-Arrhythmia Agents; D062554:NAV1.5 Voltage-Gated Sodium Channel; C568320:SCN5A protein, human; D005424:Flecainide